Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
| Revenue (TTM) | $551.69M |
| Gross Profit (TTM) | $550.59M |
| EBITDA | $324.66M |
| Operating Margin | 79.60% |
| Return on Equity | 11.00% |
| Return on Assets | 4.55% |
| Revenue/Share (TTM) | $8.44 |
| Book Value | $9.82 |
| Price-to-Book | 10.39 |
| Price-to-Sales (TTM) | 15.86 |
| EV/Revenue | 28.26 |
| EV/EBITDA | 133.06 |
| Quarterly Earnings Growth (YoY) | 351.30% |
| Quarterly Revenue Growth (YoY) | 5724.00% |
| Shares Outstanding | $64.71M |
| Float | $52.15M |
| % Insiders | 0.71% |
| % Institutions | 119.27% |
Volatility is currently expanding
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company's collaboration arrangements with Takeda related to MIMRYLOTM (rusfertide) and with Johnson & Johnson related to ICOTYDETM (icotrokinra).
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PTGX and any ticker you trade — then tracks every position and per-strategy win rate.
